Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer (Q36673680)

From Wikidata

Jump to navigation Jump to search

scientific article published on January 2004

edit

Language	Label	Description	Also known as
English	Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer	scientific article published on January 2004

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

title

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer (English)

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

main subject

phase II clinical trial

0 references

chemotherapy

1 reference

based on heuristic

inferred from title

vinblastine

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author

Simon Horenblas

series ordinal

3

object named as

S Horenblas

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

author name string

W Albrecht

series ordinal

1

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

H Van Poppel

series ordinal

2

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

G Mickisch

series ordinal

4

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

A Horwich

series ordinal

5

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

V Serretta

series ordinal

6

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

G Casetta

series ordinal

7

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

J M Maréchal

series ordinal

8

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

W G Jones

series ordinal

9

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

S Kalman

series ordinal

10

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

R Sylvester

series ordinal

11

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

published in

British Journal of Cancer

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

volume

90

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

issue

1

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

page(s)

100-105

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

cites work

Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

retrieved

30 September 2017

Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

retrieved

30 September 2017

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

retrieved

30 September 2017

Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

retrieved

30 September 2017

Mechanisms of action and clinical uses of estramustine

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

retrieved

30 September 2017

The present role of estramustine phosphate in advanced prostate cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

retrieved

30 September 2017

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

retrieved

30 September 2017

The assessment of treatment outcomes in metastatic prostate cancer: Changing endpoints

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

retrieved

28 June 2018

Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

retrieved

28 June 2018

Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

retrieved

28 June 2018

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

retrieved

28 June 2018

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

retrieved

28 June 2018

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

retrieved

20 September 2018

Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395315

retrieved

20 September 2018

Estramustine Phosphate Sodium

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601468

retrieved

21 January 2018

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/14710214

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/14710214

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/14710214

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/14710214

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantifying the amount of variation in survival explained by prostate-specific antigen

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/14710214

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/14710214

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/14710214

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/14710214

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/SJ.BJC.6601468

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

PMC publication ID

2395315

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

PubMed publication ID

14710214

1 reference

stated in

Europe PubMed Central

PMC publication ID

2395315

retrieved

15 August 2017

ResearchGate publication ID

8930509

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36673680&oldid=2264599081"